Sfoglia per AUTORE
GALLI F
Collezione ASL Biella

  

Items : 10

Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. in Scientific reports / Sci Rep. 2020 Jan 31;10(1):1918. doi: 10.1038/s41598-020-58486-6.

2020
ASL Biella

Sobrero A; Frontini L; Bergamo F; Verusio C; Lazzarelli S; Turci D; Bramati A; Biondi E; Foltran L; Nicolini M; Ricci V; Barni S; Sozzi P; Veltri E; Bagaloni I; Mucciarini C; Labianca R; Ionta MT; Zagonel V; Pella N; Ronzoni M; Massidda B; Lonardi S; Rulli E; Magnani M; Galli F; Graziano F; Galli F; Ruzzo A; et alii...

Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial. in Therapeutic advances in medical oncology / Ther Adv Med Oncol. 2020 Jan 20;12:1758835919899850. doi: 10.1177/1758835919899850. eCollection 2020

2020
ASL Biella

Galli F; Giordani P; Galli F; Aglietta M; Clerico M; Moroni M; Piazza E; Pavesi L; Silvestris N; Buonadonna A; Ciarlo A; Frassineti GL; De Placido S; Iaffaioli V; Sobrero A; Bidoli P; Zaniboni A; Labianca R; Ferrari D; Artioli F; Maiello E; Marchetti P; Dotti KF; Rimassa L; Zampino MG; Petrelli F; Banzi M; Pella N; Rosati G; et alii...

Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. in The oncologist / Oncologist. 2019 Mar;24(3):385-393. doi: 10.1634/theoncologist.2018-0442. Epub 2019 Jan 3.

2019
ASL Biella

Di Bartolomeo M; Galli F; Dotti KF; Antista M; Aglietta M; Cinieri S; Faedi M; Gori S; Cavanna L; Ciarlo A; Barni S; Leonardi F; Giordani P; Clerico M; Adamo V; Tamburini E; Re GL; Ferrario S; Buonadonna A; Tronconi MC; Pavesi L; Frassineti GL; Nicolini M; Rosati G; Labianca RF; Bidoli P; Ferrari D; Banzi M; Damiani A; et alii...

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. in Scientific reports / Sci Rep. 2019 Aug 8;9(1):11527. doi: 10.1038/s41598-019-47627-1.

2019
ASL Biella

Sobrero A; Frontini L; Bergamo F; Verusio C; Lazzarelli S; Turci D; Bramati A; Biondi E; Foltran L; Nicolini M; Ricci V; Barni S; Sozzi P; Veltri E; Bagaloni I; Mucciarini C; Labianca R; Ionta MT; Zagonel V; Pella N; Ronzoni M; Massidda B; Lonardi S; Rulli E; Magnani M; Galli F; Graziano F; Galli F; Ruzzo A; et alii...

Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2017 Sep;83:106-115. doi: 10.1016/j.ejca.2017.06.029. Epub 2017 Jul 20.

2017
ASL Biella

Galli F; Ronzoni M; Scartozzi M; Labianca R; Ferraú F; Giordano M; Corsi DC; Zagonel V; Bilancia D; Iaffaioli RV; Leone F; Zaniboni A; Marchetti P; Lonardi S; Rosati G; Nasti G; Cascinu S;

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. in British journal of cancer / Br J Cancer. 2017 Oct 24;117(9):1269-1277. doi: 10.1038/bjc.2017.289. Epub 2017 Aug 24.

2017
ASL Biella

Menghi M; Magnani M; Verusio C; Frontini L; Sobrero A; Bergamo F; Lazzarelli S; Biondi E; Bramati A; Turci D; Nicolini M; Foltran L; Ricci V; Sozzi P; Barni S; Bagaloni I; Veltri E; Ionta MT; Labianca R; Mucciarini C; Ronzoni M; Massidda B; Zagonel V; Pella N; Lonardi S; Galli F; Rulli E; Galli F; Ruzzo A; et alii...

Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: A pharmacogenetic ancillary study to TOSCA trial in Annals of Oncology

2017
ASL Biella
AO Ordine Mauriziano

Ruzzo A; Galli F; Rulli E; Lonardi S; Zagonel V; Ronzoni M; Ionta MT; Pella N; Mucciarini C; Labianca R; Veltri E; Sozzi P; Barni S; Nicolini M; Biondi E; Bramati A; Turci D; Buscaglia M; Magnani M; Graziano F; Tampellini M; Falco E; De Rosa G; Montarolo F; Dacomo R; Baratelli C; Sperti E; Di Maio M; Scagliotti GV; et alii...

Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial in Annals of oncology : official journal of the European Society for Medical Oncology

2017
ASL Biella

Ruzzo A; Galli F; Rulli E; Lonardi S; Zagonel V; Ronzoni M; Ionta MT; Pella N; Mucciarini C; Labianca R; Veltri E; Sozzi P; Barni S; Nicolini M; Biondi E; Bramati A; Turci D; Buscaglia M; Magnani M; Graziano F;

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. in Scientific reports / Sci Rep. 2014 Nov 5;4:6828. doi: 10.1038/srep06828.

2014
ASL Biella

Magnani M; Frontini L; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Turci D; Bramati A; Biondi E; Ricci V; Foltran L; Nicolini M; Veltri E; Sozzi P; Barni S; Zagonel V; Pella N; Mucciarini C; Ionta MT; Labianca R; Lonardi S; Ronzoni M; Massidda B; Rulli E; Floriani I; Galli F; Giacomini E; Graziano F; Galli F; et alii...

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer in Annals of Oncology

2014
ASL Biella
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 2

Bajetta E; Floriani I; Di Bartolomeo M; Labianca R; Falcone A; Di Costanzo F; Comella G; Amadori D; Pinto C; Carlomagno C; Nitti D; Daniele B; Mini E; Poli D; Santoro A; Mosconi S; Casaretti R; Boni C; Pinotti G; Bidoli P; Landi L; Rosati G; Ravaioli A; Cantore M; Di Fabio F; Aitini E; Marchet A; Rulli E; Cropalato Di Tullio M; et alii...